138. Postnatal Cytomegalovirus (CMV) Testing in the Neonatal Intensive Care Unit (NICU): Why?
Session: Poster Abstract Session: Big Viruses in Little People (Pediatric Viral Diseases)
Thursday, October 27, 2016
Room: Poster Hall
Background: The spectrum of postnatally-acquired CMV infection in preterm (PT) infants can range from clinically inapparent infection to severe disease. Reason(s) for evaluation of PT infants for possible acquired CMV infection is not fully known.

Methods: Retrospective review of all CMV PCR tests or cultures performed by the Virology Laboratory at Nationwide Children’s Hospital from 2008-2014. Infants in the NICU who had CMV testing from any body fluid or site after 21 days of age were identified, their electronic health records were reviewed for clinical and laboratory data, and the reason(s) for CMV testing was determined.

Results: During the 7 year study period, 5414 infants were admitted to the NICU and 153 (3%) were tested for CMV (20 [13%] positive). The median (interquartile range [IQR]) birth weight and gestational age among CMV-infected and uninfected infants were 769 (611-2436) g and 26 (25-35) wks and 845 (643-1890) g and 27 (25-33) wks, respectively. The majority were tested by PCR; only 4 were tested by viral culture. Sites of testing included urine, blood, CSF, bronchoalveolar lavage, and tracheal aspirate, with urine being the most common site. Among the 133 infants who had a negative CMV test, the most common reasons for testing were direct hyperbilirubinemia (n=45), thrombocytopenia (n=40), or transaminitis (n=20). Additional indications for testing included evaluation for sepsis, pulmonary symptoms, anemia, neutropenia, poor growth, abnormal head imaging, microcephaly, IUGR, hepatomegaly, and positive CMV testing in a sibling. In the 20 CMV-infected infants, hyperbilirubinemia (n=10) and thrombocytopenia (n=8) were the most common indications. Referral on the newborn hearing screen was the indication for testing in only 4 patients (all negative). Among those infants who tested negative, 7 were tested on more than one occasion.

CMV positive (%)

CMV negative (%)

p-value

No. of infants 

20

133

Direct hyperbilirubinemia

10 (50)

45 (34)

0.21

Thrombocytopenia

8 (40)

40 (30)

 0.44 

Transaminitis

2 (10)

20 (15)

0.74

Conclusion: Both CMV testing (3%) and detection (0.4%) were infrequent among PT infants >21 days of age in the NICU. However, when suspected, CMV was detected in 13% of evaluations. Prospective studies involving targeted newborn screening and follow-up testing for possible signs of acquired disease are urgently needed.

Meghan Ramser, MD1, Masako Shimamura, MD1, Asuncion Mejias, MD, PhD2, Douglas Salamon, BS3, Amy Leber, PhD4 and Pablo J. Sanchez, MD, FIDSA, FPIDS5, (1)Infectious Diseases, Nationwide Children's Hospital, Columbus, OH, (2)Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH, (3)Nationwide Children's Hospital, Columbus, OH, (4)Department of Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH, (5)Pediatrics, Divisions of Pediatric Infectious Diseases and Neonatology, Nationwide Children's Hospital - Ohio State University College of Medicine, Columbus, OH

Disclosures:

M. Ramser, None

M. Shimamura, None

A. Mejias, Janssen: Grant Investigator and Scientific Advisor , Consulting fee and Research grant
Alios: Consultant , Consulting fee
Abbvie: CME lecture , Speaker honorarium
Novartis: CME lecture , Speaker honorarium
Gilead: Grant Investigator , Grant recipient

D. Salamon, None

A. Leber, None

P. J. Sanchez, AbbVie, Inc: Scientific Advisor , Speaker honorarium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.